VistaGen Therapeutics Reports Fiscal Third Quarter 2017 Financial Results and Provides Corporate Update Feb 13, 2017
VistaGen Therapeutics Grants Exclusive Sublicense of Cardiac Stem Cell Technologies to BlueRock Therapeutics Dec 14, 2016
VistaGen Therapeutics Appoints Mark A. McPartland Vice President of Corporate Development and Investor Relations Oct 4, 2016
VistaGen Therapeutics Appoints Pharmaceutical CNS Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer Jun 20, 2016
